Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

Claim 1. (Currently amended) A histone deacetylase inhibitor having the formula:

$$A \xrightarrow{Q} Y \xrightarrow{Z} Q$$

wherein:

X is chosen from H and CH₃;

Y is $(CH_2)_n$ wherein n is 0-2;

Z is chosen from $(CH_2)_m$ wherein m is 0-3 and $(CH)_2$;

A is an aliphatic group including having from 3 to 14 carbons;

B is o-aminophenyl or hydroxyl group; and

Q is a halogen, hydrogen, or methyl.

Claim 2. (Cancelled)

Claim 3. (**Previously presented**) The inhibitor according to claim 1, wherein the aliphatic group is branched.

Claims 4-5. (Cancelled)

Claim 6. (Original) The inhibitor according to claim 1, wherein B is o-aminophenyl.

Claim 7. (Original) The inhibitor according to claim 1, wherein B is hydroxyl.

Claim 8. (Currently amended) A histone deacetylase inhibitor having the formula:

$$A \xrightarrow{Q} Y \xrightarrow{Z} Q \xrightarrow{N} B$$

wherein:

X is chosen from H and CH₃;

Y is $(CH_2)_n$, wherein n is 0;

Z is chosen from $(CH_2)_m$ wherein m is 0-3 and $(CH)_2$;

A is an aromatic group including having from [[3]] 5 to 14 carbons, B is hydroxy, and Q is hydrogen.

Claim 9. (Currently amended) A histone deacetylase inhibitor chosen from N-(2-Aminophenyl)-4-[(2-propyl-pentanoylamino)-methyl]-benzamide; N-Hydroxy-4-[(2-propyl-pentanoylamino)-methyl]-benzamide; N-(2-Amino-phenyl)-4-(2-propyl-pentanoylamino)-benzamide; N-Hydroxy-4-(2-propyl-pentanoylamino)-benzamide; 2-Propyl-pentanoic acid {4-[(2-amino-phenyl-phenyl)-amide; 2-Propyl-pentanoic acid (4-hydroxycarbamoyl-methyl-phenyl)-amide; 2-Propyl-pentanoic acid {4-[(2-amino-phenyl-phenyl)-amide; 2-Propyl-pentanoic acid {4-[(2-amino-phenyl-phen

phenylcarbamoyl)-ethyl]-phenyl}-amide; 2-Propyl-pentanoic acid [4-(2-hydroxycarbamoyl-ethyl)-phenyl]-amide; 2-Propyl-pentanoic acid {4-[2-(2-amino-phenylcarbamoyl)-vinyl]-phenyl}-amide; and 2-Propyl-pentanoic acid [4-(2-hydroxycarbamoyl-vinyl)-phenyl]-amide.

Claim 10. (**Currently amended**) A histone deacetylase inhibitor chosen from N-(2-Aminophenyl)-4-(butyrylamino-methyl)-benzamide; N-(2-Amino-phenyl)-4-(phenylacetylaminomethyl)-benzamide; N-(2-Amino-phenyl)-4-[(4-phenyl-butyrylamino)-methyl]-benzamide; 4-(Butyrylamino-methyl)-N-hydroxy-benzamide; N-hydroxy-4-(phenylacetylamino-methyl)-benzamide; N-hydroxy-4-[(4-phenyl-butyrylamino)-methyl]-benzamide; 4-Butyrylamino-N-hydroxy-benzamide; N-hydroxy-4-phenylacetylamino-benzamide; N-hydroxy-4-(4-phenylbutyrylamino)-benzamide; and N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-butyramide.

Claim 11. (**Currently amended**) A histone deacetylase inhibitor chosen from N-hydroxy-3-(4-phenylacetylamino-phenyl)-propionamide; N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-4-phenyl-butyramide; N-(2-Amino-phenyl)-4-[(2-phenyl-butyrylamino)-methyl]-benzamide; N-(2-Amino-phenyl)-4-[(3-phenyl-butyrylamino)-methyl]-benzamide; N-hydroxy-4-(2-phenylbutyrylamino)-benzamide; N-hydroxy-4-(3-phenylbutyrylamino)-benzamide; N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-2-phenyl-butyramide; N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-3-phenyl-butyramide; N-hydroxy-4-[(2-phenyl-butyrylamino)-methyl]-benzamide; and N-hydroxy-4-[(3-phenyl-butyrylamino)-methyl]-benzamide.

Claim 12. (**Previously presented**) A histone deacetylase inhibitor chosen from 4-Benzoylamino-N-hydroxy-benzamide; 4-(4-methyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-methyl)-Benzamide; 4-(4-methyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-methyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-methyl)-Benzoylamino-N

chloro)-Benzoylamino-N-hydroxy-benzamide; 4-(4-bromo)-Benzoylamino-N-hydroxy-benzamide; 4-(4-tert-butyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-phenyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-tert-butyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-tert-butyl)-Benzoylamino-N-hydroxy-benzamide; 4-(4-nitro)-Benzoylamino-N-hydroxy-benzamide; 4-(4-nitro)-Benzoylamino-N-hydroxy-benzamide; and Pyridine-2-carboxylic acid (4-hydroxycarbamoyl-phenyl)-amide.

Claim 13. (**Previously presented**) A histone deacetylase inhibitor chosen from N-hydroxy-4-(2-methyl-2-phenyl-propionylamino)-benzamide; N-hydroxy-4-(3-methyl-2-phenyl-butyrylamino)-benzamide; N-hydroxy-4-(3-phenyl-propionylamino)-benzamide; 4-(2,2-Dimethyl-4-phenyl-butyrylamino)-N-hydroxy-benzamide; N-hydroxy-4-[methyl-(4-phenyl-butyryl)-amino]-benzamide; N-hydroxy-4-(2-phenyl-propionylamino)-benzamide; N-hydroxy-4-(2-methoxy-2-phenyl-acetylamino)-benzamide; 4-Diphenylacetylamino-N-hydroxy-benzamide; N-hydroxy-4-[2-(4-isobutyl-phenyl)-propionylamino]-benzamide; and N-(2-Amino-phenyl)-4-phenylacetylamino-benzamide.

Claim 14. (**Previously presented**) A histone deacetylase inhibitor chosen from N-(2-Aminophenyl)-4-(5-phenyl-pentanoylamino)-benzamide; N-(2-Amino-phenyl)-4-(2-phenyl-butyrylamino)-benzamide; N-(2-Amino-phenyl)-4-(2,2-dimethyl-4-phenyl-butyrylamino)-benzamide; N-(2-Amino-phenyl)-4-(3-phenyl-propionylamino)-benzamide; N-(2-Amino-phenyl)-4-(3-phenyl-d-(3-phenyl-d-(3-phenyl-butyrylamino)-benzamide; N-(2-Amino-phenyl)-4-(3-methyl-2-phenyl-butyrylamino)-benzamide; N-(2-Amino-phenyl)-4-(2-methyl-2-phenyl-propionylamino)-benzamide; N-(2-Amino-phenyl-quality)-4-(2-methyl-2-phenyl-propionylamino)-benzamide; N-(2-Amino-phenyl-quality)-4-(2-methyl-2-phenyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-4-(2-methyl-quality)-

Amino-phenyl)-4-[2-(4-isobutyl-phenyl)-propionylamino]-benzamide; and N-hydroxy-4-[2-(S)-phenylbutyrylamino]-benzamide.

Claim 15. (**Previously presented**) A histone deacetylase inhibitor chosen from N-hydroxy-4-[2-(R)-phenylbutyrylamino]-benzamide; N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-2-(S)-phenyl-butyramide; N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-2-(R)-phenyl-butyramide; N-hydroxy-4-(3-(S)-phenylbutyrylamino)-benzamide; N-hydroxy-4-(3-(R)-phenylbutyrylamino)-benzamide; N-hydroxy-4-[3-(S)-phenylbutyrylamino]-benzamide; and N-hydroxy-4-[3-(R)-phenylbutyrylamino]-benzamide.

Claim 16. (Original) The inhibitor according to claim 1, wherein the inhibitor is an ester or salt.

Claim 17. (**Original**) A pharmaceutical composition comprising the inhibitor according to claim 1, and at least one pharmaceutically acceptable excipient.

Claims 18-19. (Cancelled)

Claim 20. (Original) The inhibitor according to claim 8, wherein m=0 and X=H.

Claim 21. (Previously presented) A histone deacetylase inhibitor having the structure:

and pharmaceutically acceptable salts thereof.

Claim 22. (Original) The inhibitor according to claim 20, wherein the compound is:

Claim 23. (Original) The inhibitor according to claim 20, wherein the compound is:

Claim 24. (**Original**) A composition comprising the inhibitor according to claim 21, wherein the composition is enriched in the S-stereoisomer as compared to the R-stereoisomer.

Claim 25. (Cancelled)